Network modeling has been effective in discovering optimal drug targets in various contexts, including previously established targets for breast cancer (e.g., SRC proto-oncogene non-receptor tyrosine kinase (SRC), mechanistic target of rapamycin kinase (MTOR)) (17) and spinal cord injury (e.g., TNF, FOS, IL6) (18). Here, FOS is linked to breast carcinoma.